This post was originally published on this site Combining Opdivo (nivolumab) with Adcetris (brentuximab vedotin) could be a promising option for people with advanced primary mediastinal B-cell lymphoma (PMBL), an aggressive and hard-to-treat disease, results from the CheckMate-436 trial show. About 70% of the patients responded to this combination, and the lymphoma completely disappeared in…
This post was originally published on this site Listening to music at home can considerably ease the severity of symptoms related to breast cancer and its treatments, helping reduce the pain and fatigue patients experience, a trial reports. It found that setting time aside nearly every day for music significantly lessened patients’ intensity of pain and…
This post was originally published on this site African American men recently diagnosed with prostate cancer are being recruited across the U.S. for the largest-ever prostate cancer study in this ethnic group. The study is a joint effort by prostate cancer researchers and experts from around the country and will seek to find out why African…
This post was originally published on this site Efforts including financial assistance, fundraising and education are underway to mark Ovarian Cancer Awareness Month. The annual September observance includes specialty lender Fifth Season Financial, which seeks to ease the financial burden of treatment of ovarian cancer, prostate cancer and other advanced-stage disorders. The lender’s Funds for Living…
This post was originally published on this site Henry Schein, a foundation devoted to promoting dental and medical health, has produced more than 27,000 comfort kits for people fighting cancer in the U.S. The kits, which are meant to make patients feel at home while receiving care away from home, were assembled by more than 2,100 Team…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BXCL701, one of BioXcel Therapeutics’ lead immunotherapies for the treatment of acute myeloid leukemia (AML). Orphan drug status is given to investigative treatments for rare diseases, defined in the U.S. as disorders that affect…
This post was originally published on this site 1: Number of times a doctor told me, “Best-case scenario, you’ll be stuck with a ‘frankenboob.’ ” 0: Odds a doctor gave me that I’d be able to get chemo in time to save my life. 3: Months a doctor predicted I’d live. 10: Age of my daughter when…
This post was originally published on this site ABP 798, a biosimilar to Rituxan (rituximab), is showing comparable efficacy results to its original product in a Phase 3 trial for non-Hodgkin’s lymphoma patients, the treatment’s co-developers, Amgen and Allergan, have announced. The therapy also has a similar safety and immunogenicity (i.e., whether the immune system reacts against…
This post was originally published on this site Health Canada and the European Commission have approved Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin plus etoposide) as a first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), an aggressive form of lung cancer. Tecentriq is an immune checkpoint inhibitor developed and marketed by Genentech, a Roche…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Puma Biotechnology’s Nerlynx (neratinib) for the treatment of HER2-positive breast cancer in women with brain metastases. Between 10 to 15% of people with metastatic breast cancer develop brain metastases. However, that number reaches up to 30% in women…
